Gut,
Journal Year:
2019,
Volume and Issue:
69(1), P. 7 - 17
Published: Oct. 31, 2019
The
International
Cancer
of
the
Pancreas
Screening
Consortium
met
in
2018
to
update
its
consensus
recommendations
for
management
individuals
with
increased
risk
pancreatic
cancer
based
on
family
history
or
germline
mutation
status
(high-risk
individuals).A
modified
Delphi
approach
was
employed
reach
among
a
multidisciplinary
group
experts
who
voted
statements.
Consensus
considered
reached
if
≥75%
agreed
disagreed.Consensus
55
main
goals
surveillance
(to
identify
high-grade
dysplastic
precursor
lesions
and
T1N0M0
cancer)
remained
unchanged.
Experts
that
those
familial
risk,
should
start
no
earlier
than
age
50
10
years
youngest
relative
cancer,
but
were
split
whether
at
55.
Germline
ATM
carriers
one
affected
first-degree
are
now
eligible
surveillance.
preferred
tests
endoscopic
ultrasound
MRI/magnetic
retrograde
cholangiopancreatography,
how
alternate
these
modalities.
Annual
is
recommended
absence
concerning
lesions.
Main
areas
disagreement
included
be
performed
hereditary
pancreatitis,
indeterminate
lesions.Pancreatic
selected
high-risk
detect
early
precursors,
research
setting
by
teams
centres
appropriate
expertise.
Until
more
evidence
supporting
available,
benefits,
risks
costs
need
additional
evaluation.
CA A Cancer Journal for Clinicians,
Journal Year:
2019,
Volume and Issue:
69(2), P. 127 - 157
Published: Feb. 5, 2019
Abstract
Judgement,
as
one
of
the
core
tenets
medicine,
relies
upon
integration
multilayered
data
with
nuanced
decision
making.
Cancer
offers
a
unique
context
for
medical
decisions
given
not
only
its
variegated
forms
evolution
disease
but
also
need
to
take
into
account
individual
condition
patients,
their
ability
receive
treatment,
and
responses
treatment.
Challenges
remain
in
accurate
detection,
characterization,
monitoring
cancers
despite
improved
technologies.
Radiographic
assessment
most
commonly
visual
evaluations,
interpretations
which
may
be
augmented
by
advanced
computational
analyses.
In
particular,
artificial
intelligence
(AI)
promises
make
great
strides
qualitative
interpretation
cancer
imaging
expert
clinicians,
including
volumetric
delineation
tumors
over
time,
extrapolation
tumor
genotype
biological
course
from
radiographic
phenotype,
prediction
clinical
outcome,
impact
treatment
on
adjacent
organs.
AI
automate
processes
initial
images
shift
workflow
management
whether
or
administer
an
intervention,
subsequent
observation
yet
envisioned
paradigm.
Here,
authors
review
current
state
applied
describe
advances
4
types
(lung,
brain,
breast,
prostate)
illustrate
how
common
problems
are
being
addressed.
Although
studies
evaluating
applications
oncology
date
have
been
vigorously
validated
reproducibility
generalizability,
results
do
highlight
increasingly
concerted
efforts
pushing
technology
use
future
directions
care.
Annals of Oncology,
Journal Year:
2020,
Volume and Issue:
31(6), P. 745 - 759
Published: March 30, 2020
Early
cancer
detection
could
identify
tumors
at
a
time
when
outcomes
are
superior
and
treatment
is
less
morbid.
This
prospective
case-control
sub-study
(from
NCT02889978
NCT03085888)
assessed
the
performance
of
targeted
methylation
analysis
circulating
cell-free
DNA
(cfDNA)
to
detect
localize
multiple
types
across
all
stages
high
specificity.
